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INTERACTION OF CANCER AND HOST
MICHAEL WrOODRUFF
.MRC Clinical and Population Cytogenetics Unit. Western General Hospital, Edinburgh
I. AMI GREATLY HONOURED in being
invited to deliver the 1.982 WValter Hubert
Lecture. Mr Hubert's generous endow-
ment is a salutary reminder that cancer is
not simply an exciting field of research,
but a disease which causes untold suffer-
ing, and that it is our responsibility to try
to lighten this burden.
Cancer is not, of course, unique to man,
but is confined to the metazoa. Unicellular
organisms are, in a real sense autonomous;
they may die in various ways if they fail
to adapt to their environment, but they
(1o not die of cancer. Multicellular organ-
isms, I suspect, get more fun out of life,
but their survival depends on the proper
functioning of an extremely complex
network of cellular interactions, and they
face the risk of the emergence of what
Michael Stoker has called asocial cells.
Asocial cells may be harmful in a purely
passive way because they replace cells
which are functionally important, and are
themselves functionally ineffective: some,
however, behave agressively as ideoso-
niatic predators (Melicow, 1982) or, in
common parlance, cancer cells.
It is convenient to think of the relation-
ship between cancer and host as one of
symbosis, using this term in its original
sense of living together irrespective of the
advantages and disadvantages of the
relationship to either partner. This con-
ceptual model is useful so long as we
remember that neoplastic cells may be
scatteredl widely throughout the host,
and that, even when this is not the case,
the entitv we call a solid tumour is not
just a mass of neoplastic cells but, as
Peter Alexander has reminded us, a
complex ecosystem in which normal cells
of many kinds, including macrophages,
lymphocytes, polymorphonuclear leuco-
cytes, fibroblasts and endothelial cells
are also commonly involved. Clearly a
tumour, in this sense, is always pleo-
clonal; an important question, to which I
shall return, is whether the neoplastic
cells are derived from a single cell or from
more than one cell.
Some tumours, including some classi-
fied as malignant on account of their
histological structure or behaviour in
tissue culture, appear to have little or no
harmful effect for months or years, and
occasionally a tumour may, for a time,
contribute something useful to the host,
for example a necessary hormone. As a
rule, however, the symbosis is antagonis-
tic, at least in one direction, and the effect
of the tumour on the host can aptly be
described as malignant. I do not propose
to discuss in detail the manifold ways in
which cancer exerts its malign influence,
despite the importance of this field of
cancer research. I would, however, remind
you in passing that they may be both local
and systemic, and that the systemic
effects include, inter alia, interference with
carbohydrate, protein and lipid metab-
olism, impaired haemopoiesis, excessive
production of particular hormones, and
impaired immunological function.
While the effect of cancer on the host is
often only too apparent, the effect of the
host on the tumour is less evident, and
this has led to the dogma, which was for a
long time accepted uncritically, that
malignant tumours are autonomous. The
meaning ascribed to this term by different34[. WVOODRUFF'
wTriters is not always clear. Obviously it
cannot meanthat tumours are autonomous
in the sense that uncellular organisms are
autonomous; what seems to be implied is,
first, that the growth of malignant
tumours is not influenced by any of the
factors that regulate the growth of normal
tissues, and secondlv, that no defence
mnechanisms (in current jargon, no forms of
surveillance) have evolved to limit the
(levelopment and proliferation of cancer
cells. In its extreme form the dogma of
autonomy is now clearly untenable; the
important question is whether host mecha-
nisms play a significant role in preventing
the development of cancer and in influ-
encing the progress of the disease when it
occurs.
RESPONSE OF TUMOURS TO
NORMAL CONTROLS
It seems clear that both local and syste-
mic mechanisms are concerned in main-
taining the orderly arrangement of cells
within tissues and the constant anatomical
relationship between tissues of different
kinds; and in controlling growth during
normal development, repair and regenera-
tion after injury. Malignant tumours are,
to say the least, relatively insensitive
to these control mechanisms, and tumour
cells do not cooperate with other cells,
in the way that normal cells do, to form
tissues specialized for particular functions,
but some measure of control and coopera-
tion can occur. Evidence of local control
is provided by the phenomenon of carcino-
ma in situ, and by the absence of vascular
invasion in some tumours, particularly at
an early stage in their development,
which suggest that epithelial basement
membranes and the walls of blood vessels
may exert a significant, if temporary,
restraining influence. Cooperation between
tumour cells and normal cells is necessarv
for the development of a tumour, and
cooperation between different neoplastic
clones may be important in some pleo-
clonal tumours. Response to systemic
control is exemplified by the fact that the
growthl of some tulmours is influenced b-
hormonal stimulation: as you will r-ecall,
this was first clearly established by Charles
Huggins and, as we now know, is contin-
gent on possession of appropriate hormone
receptors bv the ttumour cells.
SURVEILLANCE
Baasis of the hypothesis
It would, I think, be sturprising if the
metazoa had not evolved any mechanisms
to limit the emergence and proliferation
of asocial cells. This argument, in so far
as it relates to cancer, hias often beeni
challenged on the ground that many
tumours develop after reproduction has
ceased. But although many species show
a decline in reproductive function with
age, the female menopause occuirs only
in humans and a few other primate
species. Moreover, even if it were shown
that cancer in man and his immediate
ancestors was largely confined to age
groups which contribute a negligible
fraction to the birth rate, this would not
exclude the possibilitv that many tumours
are successfully aborted in early life. The
hypothesis of surveillance also gains some
support from the frequency of mutation
which, according to Cairns, is probably in
the region of 1010 in an average human
life span. Unless the proportion of muta-
tions which are potentially carcinogenic
is very small, or the number of mitotic
steps needed to achieve transformation
very large, one would expect the incidence
of cancer in the total absence of surveil-
lance to be greater than it is.
Surveillance might conceivably occUr
during carcinogenesis or after cancer has
developed, and there is evidence that both
these forms of surveillance actually occur.
Surveillance duriny carcinoyenesis
There are good reasons to believe that
carcinogenesis is, generally speaking, a
multistage process. We need a term for
cells which have gone through some, but
not all, of these stages. I propose to call
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these initiated cells, although the term was
uised originally in a more restricted sense
when chemical carcinogenesis was envis-
aged as occurring in 2 stages, initiation
and promotion. Clearly cancer would not
(levelop if all initiated cells (a) died
becauise they had undergone a mutation
w,hich was lethal; (b) were rendered
innocuous by DNA repair; (c) were
selectively shed, as Cairns has postulated,
from epithelium of the skin, gastrointes-
tinal tract and elsewhere; or (d) were
recognized and selectively destroyed by
immunological or other means.
The importance of DNA repair in this
context is well illustrated by studies of
patients with the rare autosomal recessive
hereditary disease xeroderma pigmento-
sum. Patients with this disease develop
the same types of skin cancer as normal
people, but much earlier and in much
greater frequency, and until the need for
special protection from sunlight was
realized many such patients developed
their first skin cancer before the age of 10
and died before the age of 20. The explana-
tion, as Cleaver first showed, lies in the
inability of those patients to repair UV
damage to DNA; usually because they are
unable to excise thymine dimers, occasion-
ally because postreplication repair is
defective.
The discovery that chemical, and some-
times other forms of, carcinogenesis may
be inhibited by various experimental
procedures, raises the question whether
surveillance operates against initiated
cells. This is not the only possible explana-
tion; in some cases, for example, the
inhibitory effect may be due to modifica-
tion of the metabolism of the carcinogen,
possibly as the result of macrophage
activation. It seems likely, however, that
potentiation of the host reaction to
initiated and/or transformed cells is the
main factor in the inhibition of carcino-
genesis observed by Medawar and his
colleagues in mice previously injected
with embryonic cells; and this may also
contribute to the inhibitory effect of C.
parvuni irnjection dluring carcinogenesis,
since it is otherwise difficult to explain
our observation (Woodruff et al., 1982b)
that repeated injection every 4 weeks is
much more effective than a single injec-
tion.
Surveillance after tumour development
The existence of mechanisms to elimin-
ate transformed cells or inhibit their
proliferation is suggested by the pheno-
mena of spontaneous regression and dor-
mancy, by tumour - cell population
kinetics, and by studies of the immuno-
logical and para-immunological reactions
to tumours.
Spontaneous regression.-The behaviour
ofa tumour and its histological appearance
may change throughout its life history,
even in the absence of treatment. Most
commonly the change takes the form of
what Foulds called progression, but both
in experimental animals and in man the
process may be halted, and sometimes
there is a change in the opposite direction,
as shown by partial or even complete
regression of a primary tumour or meta-
stases. Spontaneous regression of human
tumours is rare, and reports of regression
should not be accepted uncritically. Some
years ago, however, Everson and Cole
made a careful study of cases reported
between 1900 and 1966 and concluded
that in 176 ofthem regression had occurred
in the absence of treatment or after
palliative treatment which normally pro-
duces no such effect. Some of these
patients wvere alive and presented no
clinical evidence oftumour; others showed
no tumour or a marked reduction in
tumour mass at a subsequent operation;
others had died and no tumour was found
at autopsy. Some types of tumour are
much more likely to regress than others;
among the cases reviewed by Everson and
Cole, 19 out of 64 primary tumours were
neuroblastomas, 10 were carcinomas of
the bladder, 9 wN-ere soft-tissue sarcomas
and a were colo-rectal carcinomas, and
many of the metastases which regressed
were from carcinoma of the kidnev,
neuroblastoma, chorioncarcinoma and
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malignant melanoma. There have been
subsequent reports of small numbers of
cases which also appear to stand up to
critical examination. An interesting
phenomenon, to which I shall return
later, was reported by Bodenham who,
by the simple experiment of taking serial
photographs of patients with multiple
subcutaneous metastases of malignant
melanoma, showed that while the number
of metastases increased, some individual
metastases disappeared.
It must be emphasized that in speaking
of spontaneous regression the qualification
spontaneous is used in an operational
sense. In some cases infection may have
played a role; in others, changes in
hormonal balance. Often, however, it is
impossible from the published reports to
make even a plausible guess as to why
rejection occurred, and this highlights the
need for detailed study of all cases of
regression when they are first observed.
Dormancy.- Many years may elapse
between apparently complete removal of
a primary tumour and local recurrence or
the development of metastases. This
occurs particularly in patients with car-
cinoma of the kidney, breast and ovary,
and malignant melanoma. Everson and
Cole collected nearly 100 such cases in
which local recurrence or metastasis was
first recognized 10-50 years after removal
of the primary tumour. When the appear-
ance of metastases has been delayed for
many years, it is very unlikely that a
logarithmic growth curve (for which the
specific growth rate is constant) will fit the
data, but it may sometimes be possible
to fit some other curve such as the
Gompertz curve, for which the specific
growth rate varies as a continuous func-
tion of time. This becomes difficult,
however, when, as often happens, the
long-delayed metastases grow rapidly,
and it seems likely that for much of the
time that the patient appeared to be
tumour free, the size of the tumour-
cell population was stationary or nearly
so, either because the cells were not
cycling or because cell production was
balanced by cell loss. The term dormnancy,
applied originally by Hadfield to non-
cycling cells, may conveniently be used
in a broader sense and applied to all
tumours in which, for an appreciable
time, the tumour cell population remains
virtually stationarv.
Occasionally, the sudden appearance of
metastases appears to be causally related
to some definite event. This is illustrated
by a patient I first reported over 20
years ago, who developed a carcinoma
of the breast 3 years after apparently
complete excision of a melanoma on the
foot, and was treated by radical mastec-
tomy and postoperative radiotherapy.
There had been no evidence of local
recurrence or metastasis of the melanoma
prior to treatmnent ofthe breast lesion, but
6 weeks after the mastectomy sub-
cutaneous melanomatous nodules appear-
ed, first in the field ofirradiation and then
elsewhere, and about 4 months later the
patient died with metastatic melanoma
in the lungs, liver, marrow and brain.
It seems clear that the change in behaviouir
was due to some change in the host
environment, the dormant tumour cells
or both, caused by the radiotherapy or
the trauma of the operation, and there
is no knowing whether or when overt
melanoma metastases would have develop-
ed in the absence of this treatment. In a
recent review, Wheelock et al. (1981)
have stated that tumour dormancy has
not been documented in man. Their
definition of dormancy requires the exist-
ence of some form of growth restraint,
but if the case I have just described is
excluded on the grounds that no restrain-
ing mechanism has been identified, many
of the examples of dormancy of animal
tumours which they site would also have
to be excluded. Several of the animal
models reported are of great interest, but
I have time to mention only the observa-
tion of Eccles and Alexander that the
proportion of rats which developed pul-
monary tumours within 18 months of
amputation of a limb bearing a sub-
cutaneous transplant of a syngeneic fibro-
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sarcoma, was greatly increased if the rats
were exposed to 5 Gy whole-body X-
irradiation 1, 7 or 30 days after amputa-
tion, or were subjected to 7 days' con-
tinuous drainage of the thoracic duct.
Tumour cell population kinetics.-There
is convincing evidence that many animal
and human tumours contain non-cycling
cells, some of which may begin to cycle
again. It is also clear that with some
tumours there is a high rate of cell loss,
so that the tumour may grow slowly
despite a high tumour-cell birth rate.
These findings are open to various inter-
pretations, but are consistent with the
existence of some form of restraint.
Two questions of great interest, to
which I shall return later, are whether
the clonal composition of pleoclonal tu-
mours is stable or subject to change, and
the extent to which monoclonal tumour-
cell populations may become hetero-
geneous.
Immunological evidence.-The prolifera-
tion of cancer cells in vitro under a
variety of experimental conditions, and
sometimes the behaviour of tumours in
vivo, may be influenced by immuno-
logical, and what I have termed para-
immunological, mechanisms. By immuno-
logical, I mean T-cell dependent mechan-
isms triggered by tumour-associated anti-
gens (TAA), including the subset of
TAA known as tumour-associated trans-
plantation antigens (TATA) and the
subset of these which I once heard
Klein refer to as TAARIPAH (tumour-
associated antigens with a rejection-
inducing potential in the autochthonous
host). Under the heading para-immuno-
logical, I include mechanisms which do
not fulfil this criterion, but involve
macrophages, NK cells and possibly
other categories of cell which can also
participate in reactions of a strictly
immunological kind. I have recently
reviewed at some length (Woodruff, 1-980)
the evidence on which this assertion is
based. Instead ofattempting to summarize
it, I would like to devote the rest of the
lecture to considering why the hypo-
thesis of immunological surveillance is
rejected, and sometimes derided, by quite
a number of immunologists and tumour
biologists, and whether the objections
to it are well founded.
Critici,sm and countercriticism ofthe surveil-
lance hypothesis
Objections to the surveillance hypo-
thesis are of 2 kinds: general objections,
based on the fact that many tumours, in
both patients and animals, grow pro-
gressively and kill their hosts, and
attempts to treat cancer patients by
immunotherapy have on the whole proved
very disappointing; and special objections,
based on evidence of the limited role of
T-dependent mechanisms, the ambivalent
role of macrophages, and doubts con-
cerning the effectiveness of NK cells in
vivo. Unfortunately, discussion has been
marred by the failure of some critics
to make this distinction, and the use in-
stead of polemical arguments.
Failure of surveillance.-The fact that
many people and animals die of cancer
does not necessarily invalidate the sur-
veillance hypothesis, because there may
be tumours, possibly indeed many tum-
ours, which are destroyed before their
detection. The fact that active growth
may be preceded by a long period in
which the condition appears to merit the
label premalignant, or takes the form of
carcinoma in situ, is sometimes cited as
evidence to the contrary; this proves,
however, only that such lesions may
develop into aggressive tumours, not
that they always do. As regards immuno-
therapy, I would say first that it has not
been totally unsuccessful, and secondly
that past failures neither disprove the
existence of surveillance nor exclude the
possibility that we may find better ways
of making it more effective.
If surveillance mechanisms exist, they
may fail because the host reaction is
ineffective ab initio, which in turn may
be due to inherent properties of the tu-
mour, an innate deficiency in the host, or
the deleterious effect of the tumour on
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the host. Alternatively, they may fail
due to adaptive changes in the tumour
due to clonal selection, mutation and
selection, or epigenetic change. Until
recently, the possible importance of such
changes has attracted surprisingly little
attention, owing largely, I believe, to
uncritical acceptance of the dogma that
the great majority of tumours are mono-
clonal in origin, and reluctance to accept
the possibility of the generation of
diversity in a monoclonal tumour cell
population, except as a rare event.
Growing evidence of the heterogeneous
nature of the neoplastic cell component
in tumours, which I shall consider to-
wards the end of the lecture, however,
confirms my long-standing view that
adaptive changes in tumours play an
important role in their escape from
surveillance.
Limited role of T-dependent surveil-
lance.-The suggestion of Lewis Thomas
and MacFarlane Burnett that allograft
rejection is a consequence of a mechanism
which evolved as a defence against
neoplasia implies that this mechanism is
T-dependent. The discovery that, with a
few exceptions (notably lymphomas and
tumours of the skin) the incidence of
cancer is not significantly greater in
T-deficient hosts than in normal hosts,
has shown that the role of T-dependent
surveillance is, to say the least, more
restricted than originally envisaged. As
George and Eva Klein have pointed out,
however, the clinical and experimental
data are consistent with the proposition
that T-mediated surveillance plays an
important role in promoting the rejection
of cells transformed by ubiquitous onco-
genic viruses, including human cells trans-
formed by Epstein-Barr virus. I think
myself that it is reasonable to postulate
that T-mediated surveillance also elimin-
ates some immunogenic tumours induced
by environmental carcinogens, including
skin tumours induced by exposure to
UV irradiation in sunlight. Clinicians
among you will be familiar with the skin
tumour known as acanthoma, which
occurs on the face, grows rapidly, and is
easily misdiagnosed from histological sec-
tions as an anaplastic squamous-cell
carcinoma, but typically regresses com-
pletely either spontaneously or in
response to low-dose X-ray therapy.
Although I have no evidence, I suspect
that this regression is an indication that
the tumour is strongly immunogenic.
It is important to distinguish between
tumours which are not subject to T-
mediated surveillance because they lack
TAARIPAH, and those which possess
such antigens but escape from surveil-
lance, because in the latter case the
search for ways of stopping the escape
route may prove rewarding. Possible
escape mechanisms include shedding of
antigen and antigenic modulation, and
specific or non-specific impairment of the
host response. These have been discussed
many times, so I will confine myself to
3 comments.
The first concerns the work of Margaret
Kripke (1981) on UV-induced tumours
of mice which, as she has shown, are
strongly immunogenic but escape des-
truction as the result of the action of
suppressor T cells. In the light of this
discovery, and the work of Benacerraf
and others on the effect of UV irradiation
on contact-sensitivity reactions, Kripke
has drawn attention to two important
general principles. First, if the only
measure of tumour antigenicity (in the
sense of rejection-inducing antigenicity)
was the immune response in the autoch-
thonous host, the UV-induced mouse
tumours would be classed as non-anti-
genic. She suggests that much of the
difficulty in finding evidence of TSTA in
human tumours stems from the fact that
we cannot perform the same syngeneic
transplantation tests as are used to
define these antigens in inbred animals.
Secondly, the powerful suppressor activity
which permits the escape of UV-induced
tumours is evoked by the UV irradiation,
and seems to result from a mechanism
evolved to protect animals from the
dangerous consequences of over-reacting
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to minor damage to the skin caused by
such irradiation. This is a salutary remind-
er that evolution means compromise, and
the fact that surveillance is imperfect
reflects the fact that the regulatory path-
ways described for exogenous antigens
also control the immune response to
TSTA and TAARIPAH. She suggests
that "the failure to view the immune
system as a complex homeostatic mechan-
ism, regulated by positive and negative
controls, has undoubtedly hindered our
progress in the area of cancer immuno-
therapy. In fact, this deficiency may
deserve more responsibility for lack of
progress in this area than the convenient
argument that human tumours are only
weakly antigenic" (Kripke, 1981).
My second comment about escape
mechanisms concerns the suggestion of
R. T. Prehn that immunostimulation may
play an important role in tumour develop-
ment. At first Prehn appeared to regard
immunostimulation and cytotoxic killing
as mutually exclusive, but, as I have
argued elsewhere, stimulation may simply
precede killing. More recently, he (Prehn
& Outzen, 1980) has proposed that success-
ful tumours evoke reactions which pro-
vide the optimal conditions for their
growth. If he is right this would be an
interesting instance of the old adage that
nothing succeeds like success, and would
have the important consequence that, as
Prehn has suggested, manipulation of
the response in any direction might be of
therapeutic benefit.
My third comment concerns the pheno-
menon which Old and Boyse called
sneaking through, and which George Klein
has described as the least spectacular,
but possibly the most important, escape
mechanism. Why the most important?
Klein leaves us to provide the answer,
perhaps as a sort of intelligence test.
Mine is "because every developing tumour
goes through a stage when its bulk is
similar to that of the small inocula which
sneak through on transplantation", but
I have never dared to ask Dr Klein if this
secures a pass mark.
The ambivalent behaviour of macropha-
ges. It is a vexatious paradox, if I may
borrow a phrase which Charles Huggins
used in another context, that macro-
phages are found in many tumours,
sometimes in large numbers, yet in vitro
activated macrophages appear to be
selectively cytotoxic for tumour cells.
This paradox is still not completely
resolved, despite an enormous amount of
work by Alexander, Baldwin, Evans,
Hibbs, Holder, Keller, Mantovani, Keith
and Michael Moore, Russell and many
others. Faced with such an embarras de
richesse I will avoid the invidious task
of selection by commenting only on work
in which I have been personally involved.
When we found that the induction of
tumours in mice with methylcholanthrene
(MC) could, under certain conditions, be
delayed and sometimes prevented by
repeated treatment with C. parvum (CP)
(Woodruff et al., 1982c), we postulated
that those tumours which did develop in
the CP-treated animals would be resistant
on transplantation to the therapeutic
action of CP, and that their cells would
be insensitive in vitro to the cytotoxic
action ofCP-activated macrophages. When
this hypothesis was tested experimentally
neither of these predictions was con-
firmed; we did find, however, that tu-
mours which develop inCP-treated mice in
response to a small dose of MC were more
immunogenic than those which developed
after the same dose of MC in untreated
mice (Woodruff et al., 1982b). Further
experiments performed in collaboration
with W. H. McBride et al. (1982) have
shown no evidence that CP administration
during carcinogenesis affects either the
proportion or the Fc-receptor avidity of
the intra-tumour macrophages, though
the Fc-receptor avidity may increase
when tumours are passaged in CP-
treated mice.
These findings, and the work of others,
raise the question of whether intra-
tumour macrophages can be activated
during carcinogenesis by agents like CP,
and if so whether the activated macro-
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phages have any significant cytotoxic
effect on tumour cells in vivo. We have
recently developed an experimental model
which we hope will help answer these
questions. Tumour cells, alone or with
macrophages from various sources, are
deposited on millipore discs, which are
then either cultured in the wells of micro-
test plates or implanted in mice. It has
already become apparent that non-acti-
vated macrophages promote the growth of
tumour cells on these discs both in vitro,
as did tumour macrophages in the system
described in this afternoon's symposium
by Salmon (1982), also in vivo; the con-
ditions under which macrophages on
implanted discs can be activated, and
the further conditions under which acti-
vated macrophages on the discs inhibit
tumour growth in vivo, have not yet been
established.
Are NK cells cytotoxic for tumour cells
in vivo?-It is abundantly clear that
lymphoid cells from normal, untreated
mice, rats and humans may be signifi-
cantly toxic for syngeneic and allogeneic
tumour cells in vitro. It is, I think, also
clear from the work of Stutman, Herber-
man, Burton and others that these cells
form a heterogeneous group. Despite
this heterogeneity, and my reluctance to
disagree with such an acknowledged
authority as Dr Stutman on nomenclature,
I think there is much to be said for
including all these cells under a common
label; much as I dislike the word natural
in this context (for surely there is no
need to remind anyone that these cells
are neither unnatural nor supernatural?)
I prefer to refer to them all as NK cells.
Some years ago, in experiments per-
formed in collaboration with Noel Warner
and Robert Burton, when I was on a
sabbatical visit to the Walter and Eliza
Hall Institute for Medical Research in
Melbourne, we found a strong inverse
correlation between the susceptibility of a
tumour cell line to in vitro lysis by spleen
cells from syngeneic nude mice and its
capacity to grow in vivo in such mice. We
attributed both these effects to NK cells,
which we suggested could be cytotoxic
in vivo as well as in vitro. More recent
evidence, including some which we have
heard about today from Stutman (1982)
and Holden (1982), and have seen in the
poster on carcinogenesis in beige mice
by Cochran et al. (1982), points to the
same conclusions, but there is still much
to be learnt about the contributions of
NK cells to surveillance.
Heterogeneity of tumour-cell populations.
-Before concluding I would like to dis-
cuss briefly the heterogeneity of tumour
cell populations and how it might arise.
It is widely held that most (though
admittedly not all) tumours are mono-
clonal. This may be so if we consider
only those tumours which arise under
conditions in which the chance of trans-
formation is small, as may indeed quite
often be the case with human tumours;
under other conditions, however, one
would expect to see tumours which are
pleoclonal, at least at an early stage in
their development. Apart from the special
case of plasmacytomas, many of the
claims for monoclonality of human tu-
mours are based on studies of tumours in
women heterozygous for the gene on the
X-chromosome that determines which of
the two isoenzymes of glucose-6-phos-
phate dehydrogenase (G6PD) is produced
by a cell. Owing to the inactivation of
one X-chromosome in all somatic cells,
the normal tissues of these women are
mosaics, but this mosaicism should not
exist in a monoclonal tumour cell popula-
tion. Various difficulties in interpretation
arise which I do not propose to discuss
here; fortunately, the discovery in feral
mice ofa form (A) ofthe enzyme phospho-
glycerate kinase 1 (PGKl) which differs
from the B form found in common
laboratory mouse strains, and the develop-
ment of congenic strains which are
homozygous for one or other isoenzyme,
has made it possible to study the problem
under controlled experimental conditions
without the necessity of embarking on a
long safari. My colleagues and I have
engaged in a study of this kind (Woodruff
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et al., 1982a). Not surprisingly, we
have confirmedthatfibrosarcomas induced
in mice with doses of MC which result in
tumours in most of the animals, are often
pleoclonal. This can be stated categori-
cally, because with several tumours we
have isolated both A and B clones, and
shown either that these were tumori-
genic on transplantation or that they were
markedly polyploid.
Three results are of particular interest
in present context. First, the extent to
which one or other isoenzyme is expressed
by a tumour may change dramatically
in the course of tissue culture or on
transplantation. This raises the possibility
that similar changes may occur in the
autochthonous host during carcinogenesis
and progression, and when a tumour
metastasizes or recurs locally after in-
adequate attempts at ablation. Experi-
mental evidence of the heterogeneity of
tumour cells is provided by the work of
Poste et al. (1981) on the effect of inter-
actions among clonal subpopulations on
the stability of the metastatic phenotype
in pleoclonal populations of the B16
mouse melanoma, and by the work we
heard about this morning from Ian Hart
(1982).
Secondly, clones isolated by serial
dilution, of which we now have more
than 200, are less readily transplantable
than uncloned tumour-cell suspensions,
and some clones are less readily trans-
plantable than others. This suggests that
clones resistant to host defences are
selected when a pleoclonal population is
transplanted, or that some clones require
the cooperation of others to survive. The
first hypothesis gains support from our
recent observation that clones which
fail to grow in normal mice may grow in
thymectomized, irradiated mice protected
with cytosine arabinoside (as described by
Steel et al., 1978), which were prepared
for us by Dr John Hay.
Thirdly, we have isolated from one
tumour many subpopulations expressing
both enzyme phenotypes. On recloning
at extreme dilution (on average 0.5-1
cell/well, of which about one-third of the
cells were clonogenic) most of the sub-
populations again expressed both pheno-
types, though a few expressed only one.
The explanation must await karyotyping
and other studies, but our provisional
hypothesis is that we have isolated clones
of hybrid cells which have arisen either
in the mouse or during tissue culture,
and that some have reverted to cells
expressing only one enzymal phenotype
as the result of chromosome loss.
The tumours we have studied cannot of
course be assumed to reflect the behaviour
of human tumours in general, or even
those due to exposure to environmental
carcinogens in which, as a rule, the total
dose is accumulated over a long time;
nor does the B16 mouse melanoma used
by Poste and others necessarily reflect
the behaviour of human malignant
melanomas. But many human tumours
appear to have a multifocal origin or,
at least, to develop in a field of abnormal,
possibly initiated, cells, which suggests
that they may have been pleoclonal
initially, even when only one clone has
survived the dual hazards of host defence
and interclonal competition. Moreover,
even when the multistage journey to
malignant transformation is completed
by only one cell, there is still the possible
generation of diversity within this clone
by mutation or epigenetic change, and
subsequent selection. The simultaneous
regression of some melanoma metastases
and progression of others which, as I
mentioned earlier, was first reported by
Bodenham and the recent observa-
tion of Albino et al. (1981) that 3 estab-
lished lines of melanoma cells from
different metastases in the same patient
showed differences in growth rate, mor-
phology, pigmentation, and expression of
surface antigens and glycoproteins, sug-
gest that this phenomenon occurs in
human tumours, as well as in tumours of
experimental animals.
A personal view.-Let me end on a
personal note. One of my colleagues, in a
recent seminar, quoted a remark which
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she attributed to Gordon Sato, to the
effect that one must have a prejudice
when attacking a scientific problem.
I think there is much truth in this anti-
Popperian aphorism, though I would
prefer the word conviction to prejudice.
Karl Popper (1968) performed a great
service for science by his forceful reitera-
tion of the need to test and retest our
hypotheses experimentally. But if all
our energy is devoted to trying to dis-
prove current hypotheses we shall have
no energy left to generate new ones. Our
understanding of cosmology and gravita-
tion was advanced, not impeded, by
Galileo's conviction that the earth does
move, and the development of genetics
was advanced by Darwin's convictions
about the origin of species, though many
of their ideas on these subjects have
been superseded. It is, therefore, not
wrong but necessary in science to have
convictions; what is wrong is to neglect
to test them, or to maintain them in the
face of evidence to the contrary.
I remain convinced that the concept of
surveillance in relation to cancer is
soundly based, and that advances in the
prevention and treatment of cancer will
stem from a deeper understanding of the
complex interaction of cancer and host;
but, who knows, I may be wrong.
I am deeply indebted to Professor H. J. Evanls for
the privelege of working in his Unit, and to the
Medical Research Council for a Project Grant. I am
also grateful to the many colleagues I have named
for their collaboration and for allowing me to quote
the results ofjoint work and to Grune & Stratton Inc.
for permission to quote freely from my book, The
Interaction of Cancer and Host-Its Therapeutic
Significance.
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